Charles River Laboratories International, Inc. (CRL) Receives Average Rating of “Hold” from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has received a consensus recommendation of “Hold” from the eight research firms that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $90.92.

A number of research firms recently weighed in on CRL. Barclays PLC set a $90.00 target price on shares of Charles River Laboratories International and gave the company a “hold” rating in a research report on Saturday, May 13th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $95.00 target price (up previously from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Jefferies Group LLC reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday. Finally, Citigroup Inc. reissued a “neutral” rating and issued a $104.00 price objective (up previously from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th.

Shares of Charles River Laboratories International (NYSE CRL) traded up 0.64% on Tuesday, hitting $95.76. The company had a trading volume of 525,918 shares. The company has a 50 day moving average of $91.73 and a 200-day moving average of $85.30. The company has a market cap of $4.56 billion, a price-to-earnings ratio of 28.02 and a beta of 1.00. Charles River Laboratories International has a 12-month low of $67.20 and a 12-month high of $95.83.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, May 10th. The medical research company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.15. The business had revenue of $445.80 million during the quarter, compared to the consensus estimate of $437.04 million. Charles River Laboratories International had a net margin of 9.28% and a return on equity of 27.46%. The firm’s revenue for the quarter was up 25.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.98 earnings per share. On average, analysts forecast that Charles River Laboratories International will post $5.10 earnings per share for the current year.

In other news, insider David Ross Smith sold 945 shares of the firm’s stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $95.00, for a total transaction of $89,775.00. Following the completion of the sale, the insider now owns 14,203 shares in the company, valued at approximately $1,349,285. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director George Massaro sold 1,130 shares of the firm’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $88.30, for a total transaction of $99,779.00. Following the sale, the director now owns 15,831 shares of the company’s stock, valued at approximately $1,397,877.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,051 shares of company stock valued at $1,208,566. 2.20% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. boosted its stake in shares of Charles River Laboratories International by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock valued at $135,000 after buying an additional 526 shares during the period. Bessemer Group Inc. boosted its stake in shares of Charles River Laboratories International by 2.3% in the fourth quarter. Bessemer Group Inc. now owns 1,933 shares of the medical research company’s stock valued at $147,000 after buying an additional 43 shares during the period. Tyers Asset Management LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter valued at $188,000. Massmutual Trust Co. FSB ADV acquired a new stake in shares of Charles River Laboratories International during the fourth quarter valued at $199,000. Finally, Wsfs Capital Management LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter valued at $205,000. Institutional investors and hedge funds own 97.77% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Receives Average Rating of “Hold” from Analysts” was reported by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.themarketsdaily.com/2017/06/16/brokerages-set-charles-river-laboratories-intl-inc-crl-price-target-at-92-75-updated.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply